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Background: High-dose chemotherapy (HDC) has been widely utilized in high-risk breast cancer, but
it may induce cardiac toxicity. Cardiac dysfunction may become evident weeks or months after HDC
and, to date, no early markers of myocardial injury that are able to predict late ventricular impairment
are available. We investigated the role of plasma troponin I (TnI) in this setting.
Patients and methods: We measured TnI plasma concentration after HDC in 211 high-risk breast
cancer women (46 ± 11 years, mean ± SD). According to TnI value (<0.5 or ≥0.5 ng/ml), patients were
allocated into a troponin positive (TnI+; n = 70) and a troponin negative (TnI–; n = 141) group. All
patients underwent left ventricular ejection fraction (LVEF, Echo) examination during the following
12 months.
Results: LVEF progressively decreased in the TnI+ group but not in the TnI– group. In TnI+ patients a
close relationship between the TnI increase, as well as the number of positive TnI assays, and the maxi-
mal LVEF decrement, was found (r = –0.92, P <0.0001 and r = –0.93, P <0.0001, respectively).
Conclusions: In our population, the elevation of TnI soon after HDC accurately predicts the develop-
ment of future LVEF depression. In this setting, TnI can be considered a sensitive and reliable marker
of myocardial damage with relevant clinical and prognostic implications.
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Introduction
Breast cancer is a major cause of cancer death in women. In an
attempt to improve the prognosis of patients with high risk
breast cancer disease, more and more aggressive chemotherapy
schedules have been proposed. High-dose chemotherapy
(HDC) has been increasingly used for the treatment of high-
risk primary breast cancer [1], although its effects on response
rate, response duration and survival are still controversial
[2–6]. HDC is frequently complicated by considerable toxic
events; in particular, cardiotoxicity represents one of the side
effects impacting on patient’s survival and quality of life,
independent of the cancer stage. Beyond early cardiotoxicity,
which occurs during or soon after treatment, the development
of cardiac dysfunction many months after the last administra-
tion of chemotherapic drugs, is increasingly recognized [7–9].
Usually, cardiac involvement becomes clinically manifest as
a poor prognosis cardiomyopathy leading to heart failure.
Nevertheless, with the increasing availability of echocardio-
graphy, it has become evident that chemotherapy-induced left
ventricular impairment is often asymptomatic.
Hence, there is a rapidly growing expectation, in both
oncologists and cardiologists, for new non-invasive and cost-
effective opportunities for the early identification of patients
most likely to develop late ventricular dysfunction. This
would allow clinicians to closely monitor cardiovascular
function, to prevent cardiac impairment and to support cardiac
function with a specific heart failure treatment. In addition, it
might be possible to adjust chemotherapeutic dosages or to
shift patients with increased cardiac risk toward a less cardio-
toxic schedule.
Acute myocardial injury can be sensitively and accurately
identified by measurement of plasma concentration of
troponin I (TnI), one of the contractile proteins of the myo-
cardium [10]. A rise in the concentration of TnI in the circula-
tion indicates various degrees of myocardial cell damage, and
its determination provides the highest diagnostic accuracy for
detecting myocardial cell necrosis [11]. The clinical and prog-
nostic significance of TnI in acute coronary syndromes is well
appreciated [12–14], but the possible application of this
 by guest on June 28, 2012
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
711
peptide in the detection of HDC-induced cardiac damage, as
well as in the short- and long-term cardiac risk assessment of
breast cancer patients undergoing this kind of treatment, has
never been investigated.
Patients and methods
Study population
All consecutive women receiving HDC in our institution for poor prog-
nosis breast cancer were enrolled from July 1997 to October 1999. HDC
exclusion criteria were as follows: history of ischemic, valvular and
hypertensive heart disease; uncontrolled hypertension; left ventricular
ejection fraction (LVEF) <50%; acute or chronic renal insufficiency
(serum creatinine >1.5 mg/dl); and liver disease (bilirubin >2 mg/dl,
aspartate aminotransferase >2× the upper limit of normal). Patients who
did not complete the 1-year observation period after HDC because of
oncologic death, loss to follow-up or the beginning of a new chemo-
therapeutic treatment were also excluded. Two hundred and eleven women
(age 46 ± 11 years, mean ± SD) were included in the study. Eighteen
patients were receiving calcium antagonist agents for mild hypertension;
none were receiving β-blockers, angiotensin converting enzyme inhibit-
ors or diuretics. HDC was administered, as adjuvant treatment, in 112
high-risk untreated breast cancer patients (T1–T3, N1 or N2, 10 involved
axillary nodes and positive estrogen receptor tumor or five involved
axillary nodes and negative estrogen receptor tumor). HDC was also
utilized in  99 patients preoperatively treated with neo-adjuvant chemo-
therapy with residual more than eight involved axillary nodes, or more
than five involved and negative estrogen receptor tumor. None of the
patients had been previously treated with radiotherapy.
Informed consent was obtained from all patients before participation in
the study, and the protocol was approved by the ethics committee of our
institution.
Study protocol
Clinical examination, electrocardiogram and chest X-ray were part of the
preliminary evaluation. All eligible patients received HDC after breast
surgery in different drug combinations, according to our institution’s
oncological protocols. Patients previously treated with anthracyclines
(n = 75) were assigned to ICE (ifosfamide–carboplatin–etoposide; n = 43)
or TICE (taxotere–ifosfamide–carboplatin–etoposide; n = 32) regimens.
The remaining patients were treated accordingly to EC (epirubicin–cyclo-
phosphamide; n = 51) and TEC (taxotere–epirubicin–cyclophosphamide;
n = 85) schemes (Table 1). All drugs were administered intravenously, via
a central venous catheter. Cycles were delivered at 28-day intervals three
times, and each cycle was supported by autologous peripheral blood
progenitors cells and filgrastim (granulocyte colony-stimulating factor,
G-CSF) [15]. Peripheral blood progenitors cells were mobilized by
filgrastim and collected before the beginning of chemotherapy. After
completion of HDC, all patients received radiotherapy to the chest wall in
the case of mastectomy (n = 78; 41 to the left side), or to the residual breast
in the case of breast-conserving surgery (n = 133; 81 to the left side).
Plasma TnI concentration was measured before and immediately after,
and then 12, 24, 36 and 72 h after every single cycle of HDC (18 assays for
each patient).
Cardiac assessment was performed by echocardiography and electro-
cardiography. In all patients, LVEF (biplane method according to
Simpson’s rule) was evaluated before HDC and 1, 2, 3, 4, 7 and 12 months
after the end of the treatment (i.e. starting 3 months after the baseline
evaluation).
Electrocardiogram was performed before and after each HDC cycle
and then at all follow-up checks. For all patients, the duration of the
follow-up was 14 months from the baseline evaluation. During this
period, none were treated with other chemotherapic drugs and all patients’
management decisions were made without the knowledge of their TnI
result.
Laboratory methods
The laboratory method employed for TnI determination was an immuno-
enzymatic fluorescent assay (Stratus II; Dade, International Inc., Miami,
FL, USA). This method utilizes two TnI-specific monoclonal antibodies
for independent epitopes [16] and has no detectable cross reactivity with
skeletal muscle TnI. The lower limit of detection was 0.35 ng/ml; since at
levels between 0.4 and 1.5 ng/ml, the coefficient of variation is 9–14%,
we set the cut-off level at 0.5 ng/ml. After centrifuging, plasma was stored
immediately at –30°C. All samples were analyzed in duplicate, with an
interassay variability ≤0.1 ng/ml and all ‘positive’ samples were immedi-
ately re-tested to confirm the result.
Statistical analysis
The LVEF values were analyzed using a repeated measures model taking
into account the correlation among the time periods with an unstructured
covariance matrix. Time was treated as a factor and the interaction
between time, and TnI value was included in the model. All interactions
were tested using F tests based on type 3 sums on squares. Least squares
means and corresponding confidence intervals of time × TnI value inter-
actions were calculated. All calculations were performed using PROC
Table 1. High-dose chemotherapy schedules
Ac, anthracyclines; EC, epirubicin–cyclophosphamide; TEC, taxotere–epirubicin–cyclophosphamide; ICE, ifosfamide–carboplatin–etoposide; 
TICE, taxotere–ifosfamide–carboplatin–etoposide.
EC TEC ICE TICE
Patients (n) 51 85 43 32
Patients pre-treated with Ac (%) 0 0 100 100
Drugs and dosages Epirubicin 200 mg/mq Taxotere 85 mg/mq Ifosfamide 10 g/mq Taxotere 85 mg/mq
Cyclophosfamide 4 g/mq Epirubicin 200 mg/mq Carboplatin 1.2 g/mq Ifosfamide 10 g/mq
Cyclophosphamide 4 g/mq Etoposide 1.2 g/mq Carboplatin 1.2 g/mq
Etoposide 1.2 g/mq
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MIXED in SAS. Differences in LVEF values at baseline between the two
groups were analyzed using a generalized linear model. Significance was
taken at the 5% level. Results are presented as mean ± SD. Differences in
TnI positivity percentage among the different schedules utilized were
analyzed according to logistic regression and contrasts method.
Results
All patients underwent HDC without acute cardiological side
effects during or soon after the administration of the drugs.
Ten patients (4.7%) developed symptoms of heart failure
during the follow-up. Seven of them reported only exertional
dyspnea; three women developed overt heart failure. In these
ten patients heart failure treatment was started and they were
not considered in the following period of follow-up.
At the baseline evaluation, as well as before each cycle of
HDC, the TnI value was within the normal range in all cases.
A rise in the concentration of circulating TnI was detected in
70 of the 211 patients treated (33%) and, when the total
number of HDC cycles was considered, in 120 of 633 (19%)
cycles. Figure 1 shows the percentage distribution of TnI
positive (TnI+) assays at the various time points considered
and of TnI+ patients after each cycle. Fifty-two per cent of TnI+
patients had only one positive sample, 11% had two, 8% had
three, 7% had four, 8% had five, 7% had six and 4% had
seven.
Taking into consideration the different schedules, the per-
centage of patients with TnI positivity was 53% in EC, 31% in
TEC, 28% in ICE and 16% in TICE. A significant difference
was observed among the various schedules, except between
TEC and ICE groups. In TnI+ group, 17 of 75 (23%) patients
had previously received anthracyclines in the neoadjuvant
setting.
No electrocardiographic changes were observed in any of
the patients, both after HDC and at the follow-up checks.
Patients were grouped according to the maximal TnI value
detected after HDC into a negative troponin group (TnI–;
n = 141) and a positive troponin group (n = 70). The TnI–
group was defined by a value <0.5 ng/ml in every determina-
tion, and the TnI+ group was defined by a value ≥0.5 ng/ml at
least at one of the points of measurement considered (mean
value 0.9 ± 0.5 ng/ml; range 0.5–2.3). The two populations
were similar with regard to age and other clinical character-
istics (incidence of hypertension, smoking habits, kind of
surgical intervention, stage of neoplasm).
At the baseline evaluation, LVEF was similar in the
two groups, and, in all cases, was within the normal range
(63 ± 4% and 62 ± 5% in TnI+ and TnI–, respectively; P = 0.23,
not significant). After HDC, there was a different behavior of
LVEF in the TnI+ group compared with the TnI– group
(Figure 2). In the TnI+ group, a significant reduction in LVEF
was observed after the first month of follow-up. Thereafter,
LVEF further worsened during the follow-up period. The TnI–
group did not show any significant decrease in LVEF during
the entire period of observation.
In TnI+ group, a strong relationship between the TnI
maximal value detected after HDC and the LVEF maximal
reduction observed during the follow-up was found (r = –0.92;
P <0.0001). A significant correlation was also detected
between the number of positive TnI assays per patient and the
LVEF maximal decrement (r = –0.93; P <0.0001) (Figure 3).
Figure 1. (A) Percentage distribution of TnI+ assays after each cycle at 
the various time points considered. (B) Percentage distribution of TnI+ 
patients after each cycle.
Figure 2. LVEF percentage changes during the follow-up in TnI+ 
(squares) and TnI– (circles) patients. *P <0.001 versus before HDC; 
§P <0.01 versus TnI– group.
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The 10 patients which developed symptoms of heart failure
during the follow-up, had repeated positive values (range
5–7/18) of TnI after HDC (after EC in four cases, after TEC in
two, after ICE in two and after TICE in two). At the time of
symptoms onset, LVEF ranged between 30% and 45% in the
seven patients having mild heart failure symptoms, and it was
<30% in the three women with overt heart failure.
Figure 4 shows the different LVEF pattern in TnI+ versus
TnI– patients, according to the four different chemotherapy
regimens. A similar LVEF course was observed, independ-
ently from the HDC schedule.
There was no difference in LVEF reduction between
patients who received radiotherapy to the left chest and those
in whom it was given to the right chest.
Discussion
HDC has been widely utilized as adjuvant therapy for women
with high-risk primary breast cancer [1–6]. However, thera-
peutic potential of this approach is limited by both acute and
chronic toxicity [7–9, 17–19].
While its major acute toxic effects can be largely overcome
with hematological growth factors, stem-cell infusion and
appropriate supportive care, cardiotoxicity remains an un-
resolved problem. Typically, cardiac involvement becomes
manifest late in the course of the natural history of the cardiac
disease; it is generally considered to be irreversible and can
lead to overt heart failure. Cardiotoxicity is an emerging
problem commensurate with the growing number of long-
term breast cancer survivors and the increasing number of
patients treated with adjuvant chemotherapy.
To detect HDC-induced cardiac damage, regular monitor-
ing of cardiac function is recommended at present [7, 20]. It
could be performed during chemotherapy to allow administra-
tion of the highest dose without inducing severe cardiac
damage. After completion of chemotherapy, monitoring must
be carried out again to identify cardiac damage at an early pre-
clinical stage, in order to prevent further heart function deteri-
oration by timely medical intervention. The limit of such an
approach is that it is too late. In fact, cardiac damage is usually
detected when functional impairment has already occurred
[17, 19]. Furthermore, the evidence of an unaffected heart
function does not exclude the possibility of a future cardiac
deterioration [19, 21, 22]. Accordingly, several methods of
identifying cardiotoxicity, before it causes irreversible cardiac
function depression, have been proposed. Among these are the
following: radionuclide imaging tests utilizing monoclonal
antimyosin antibodies or metaiodobenzylguanidine [23, 24],
study of cardiac autonomic function [25] and endomyocardial
biopsy [26]. Although some of these techniques are very sen-
sitive in the detection of heart damage, they have specific lim-
itations and poor positive predictive value.
The early detection of myocardial damage is one of the
major challenges to contemporary cardiology. Many recent
studies have elucidated the value of both TnT and TnI in the
diagnosis and in the risk assessment of acute coronary syn-
Figure 3. (A) Scatterplot of percent reduction against TnI maximal value 
in patients with positive TnI. (B) Scatterplot of LVEF against number of 
positive TnI assays in TnI+ group.
Figure 4. LVEF pattern in TnI+ (filled symbols) and TnI– patients 
(open symbols), according to the four different chemotherapic regimens. 
Diamonds, EC; squares, TEC; triangles, ICE; circles, TICE. For 
definition of abbreviations see Table 1. Standard deviations were 
omitted for clarity.
 by guest on June 28, 2012
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
714
dromes [10–14]. Our study addresses the question of whether
TnI measurement gives significant information in a popula-
tion of patients with aggressive breast cancer undergoing
HDC, in relation to its possible direct cardiotoxic effect.
Our data demonstrate that TnI is a risk marker for future
development of significant LVEF reduction. This information
cannot be usually obtained by conventional criteria, such as
symptoms, and electrocardiographic and echocardiographic
changes. The innovative aspect of this new marker of myo-
cardial damage is that it gives us this information at a very
early phase (immediately after the HDC administration), long
before a functional impairment can be detected with the other
available techniques. The possibility of identifying patients
who will develop late myocardial function depression is a
golden opportunity for both oncologists and cardiologists.
This information can permit oncologists to modify, or to dis-
continue, the oncologic regimen, or to shift patients toward a
less cardiotoxic schedule. In addition, it could allow cardio-
logists to support cardiac function or to prevent heart dys-
function with cardioprotective agents or with cardiovascular
therapy [27, 28]. This issue is particularly important in
patients with cancer disease in which onset of cardiac
dysfunction, even asymptomatic, importantly limits the thera-
peutic opportunities and negatively influences the prognosis.
On the other hand, the presence of cardiac dysfunction, either
symptomatic or not, could be widely counterbalanced by
improvement in survival due to enhanced control of the
cancer. In contrast, the development of overt heart failure
might negatively affect the overall long-term survival, inde-
pendently from the cancer stage. Compared with other meth-
ods of cardiac damage detection, TnI appears to be a more
sensitive and specific, and less costly method for the early
identification of cardiotoxicity.
The observation that pathological TnI release and signifi-
cant LVEF reduction can also occur after schedules that are
classically considered to have low (TICE) or no (ICE) cardio-
toxic properties suggests that their toxic effects probably
derive from the combined interaction of different drugs.
Indeed, in a previous report, congestive heart failure has been
described as occurring when intermediate cumulative doses
with multi-agent chemotherapy were utilized [29]. Further-
more, it can be speculated that, in our patients, the previous
treatment with anthracyclines might have played either a
synergic or a cumulative role.
Evidence of TnT and TnI release after chemotherapy was
previously shown in animal studies [30] and in children under-
going anthracycline chemotherapy [31]. In these studies, the
elevated troponin levels were correlated with acute clinical
toxicity. In addition, Missov et al. [32] described TnI increase
during the course of anthracycline chemotherapy in patients
with hematological malignancies. However, this is the first
study that correlates the presence of TnI increase with the
long-term development of cardiac dysfunction, even asympto-
matic.
Although the small amount of TnI increase, at least in
comparison with that observed in acute coronary syndromes,
indicates that only a minimal acute necrosis occurs during
HDC, the clinical interest of this increment is quite relevant, as
the minor myocardial damage seems to precede left ventricu-
lar systolic impairment. Both the underlying mechanism(s)
and the time course of the cardiac damage are unclear, and
further studies are needed to elucidate whether patients with
TnI acute increment and with following LVEF reduction will
develop an irreversible dilated cardiomyopathy at a longer
observation period. On the other hand, normal TnI values
clearly identify patients at lower risk, in which no cardiac
damage, at least in the first year after HDC, occurs. In brief, at
the present time, TnI result allows separation of patients in
which a close monitoring of cardiac function is mandatory
from those in which it is not required.
In addition to these prognostic data, TnI also provides us
with quantitative information. Indeed, we observed a close
relationship between the TnI maximal value after HDC, as
well as the number of positive samples after each HDC cycle,
and the degree of LVEF reduction (Figure 3). These findings
suggest that the HDC-induced myocardial injury, although
limited, is an ongoing phenomenon that, once elicited by these
drugs, could last for several days or months and results in a
cumulative effect reflected by a global left ventricular dys-
function. A more prolonged TnI follow-up could permit us to
better understand the time course of the myocardial damage,
as well as to better assess the long-term outcome of high-risk
patients (TnI+). In this regard, the lack of information about
TnI behavior after the first 72 h does not allow for obtaining
more accurate indications concerning a possible different
evolution of cardiac dysfunction among TnI+ patients.
Despite this limitation, however, the amplitude of TnI
elevation and its release pattern in the days following the
oncologic treatment allows us to anticipate, for each patient,
the cardiac functional status that will characterize the first year
after HDC.
Conclusion
In patients undergoing HDC for aggressive breast cancer, TnI
is a sensitive, specific and low cost way to predict the develop-
ment of ventricular systolic dysfunction in the months to
follow, as well as the degree of cardiac impairment. The
possibility of carrying out a risk stratification in such a patient
population, in a very early phase, has relevant clinical and
prognostic implications.
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